Abstract #1033

13C Hyperpolarized Anticoagulants

Joachim Bargon¹, Johannes Bernarding², Rahim Rizi³, Hans-Wolfgang Spiess⁴, Kerstin Mnnemann⁴, Meike Roth⁴, Ute Bommerich⁵

¹Institute of Physical and Theoretical Chemistry, University of Bonn, Bonn, NRW, Germany; ²Institute of Biometry, University of Magdeburg, Magdeburg, Germany; ³Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States; ⁴NMR, Max-Planck Institute of Polymers, Mainz, Germany; ⁵Institute of Neurobiology, Magdeburg, Germany

Anticoagulants like warfarin, phenprocoumon, and pentoxifylline are used to alleviate the disabling consequences of strokes, the leading cause of disability in the US and third leading cause of death. Similarly, the phosphodiesterase inhibitor pentoxifylline inhibits multiple processes including inflammation, coagulation, and edema that lead to neonatal hyperoxic lung injury, whereby. bronchopulmonary dysplasia is a leading cause of mortality and morbidity in preterm infants despite improved treatment. All of these anticoagulants can be 13C-hyperpolarized for 13C-MRI/MRS-studies upon parahydrogenation of suitably unsaturated precursors, preferably at low magnetic fields. Differing from DNP, this procedure can provide a steady flow of 13C-hyperpolarized drugs.